AyuVis Research

AyuVis is a near clinical-stage pharmaceutical company developing small-molecule immunotherapeutics to prevent & treat acute and chronic respiratory diseases, with bronchopulmonary dysplasia (BPD) as the initial lead indication. AyuVis compounds modulate the innate immune system to treat inflammation and infection and have been evaluated in several preclinical disease models, using a variety of formulations and delivery routes with positive therapeutic outcomes. In particular, its novel series of small molecules convert circulating white blood cells into special macrophage immune cells that reduce inflammation, reduce bacteria load, and promote tissue regeneration.

The FDA granted AyuVis Orphan Drug and Rare Pediatric Disease Designations for AVR-48 to prevent BPD in at-risk preterm infants. The company has completed safety, efficacy testing, GMP manufacturing, and a regulatory filing is in preparation for Phase 1 to be filed in mid-2023 to deliver a first-in-class drug candidate for clinical development.

AyuVis has also identified hit/lead compounds to expand the pipeline to include ventilator-associated pneumonia (VAP), acute respiratory distress syndrome (ARDS), complicated intra-abdominal infection (cIAI), necrotizing colitis (NEC), acute kidney injury, systemic inflammatory response syndrome, fibrosis, and ocular diseases including retinopathy of prematurity (ROP).

AyuVis has a strong leadership team with cross-disciplinary experience in drug discovery, development, and commercialization, merger & acquisition, IPO and is aided by a number of seasoned business and scientific advisors in the field. The company has raised $4.17 M in non-dilutive SBIR and Research grants from NIH (R43, R44, R61) and $5.1 M in angel private funding. Currently raising $16M in Series A to fund clinical trials.